Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Receivables (2019 - 2025)

Silence Therapeutics' Receivables history spans 7 years, with the latest figure at $28000.0 for Q3 2025.

  • On a quarterly basis, Receivables fell 92.52% to $28000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $28000.0, a 92.52% decrease, with the full-year FY2024 number at $972000.0, up 243.48% from a year prior.
  • Receivables hit $28000.0 in Q3 2025 for Silence Therapeutics, down from $85000.0 in the prior quarter.
  • Over the last five years, Receivables for SLN hit a ceiling of $15.4 million in Q2 2023 and a floor of $28000.0 in Q3 2025.
  • Historically, Receivables has averaged $2.5 million across 5 years, with a median of $612205.0 in 2021.
  • Biggest five-year swings in Receivables: surged 496.74% in 2022 and later tumbled 99.6% in 2025.
  • Tracing SLN's Receivables over 5 years: stood at $446191.5 in 2021, then soared by 140.53% to $1.1 million in 2022, then crashed by 73.63% to $282982.6 in 2023, then soared by 243.48% to $972000.0 in 2024, then tumbled by 97.12% to $28000.0 in 2025.
  • Business Quant data shows Receivables for SLN at $28000.0 in Q3 2025, $85000.0 in Q2 2025, and $41000.0 in Q1 2025.